Summary & Overview
CPT 0266U: Praxis Transcriptome NGS Transcriptome Analysis
CPT code 0266U identifies a proprietary NGS-based transcriptome assay, Praxis Transcriptome from Praxis Genomics LLC, designed to detect gene expression changes linked to constitutional and other heritable disorders. As a PLA code, 0266U applies exclusively to this single manufacturer’s test, which is performed on blood, frozen tissue, or FFPE specimens. Its specificity matters nationally because PLA codes standardize reporting for unique commercial tests and inform coverage and billing practices across payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, the test’s role in hereditary disorder evaluation, and typical sites of service. The publication provides benchmarks and payer coverage notes where available, highlights policy considerations relevant to proprietary laboratory tests, and summarizes coding and billing implications tied to PLA designation.
The report is intended for billing professionals, laboratory directors, and policy analysts seeking clear guidance on the clinical description, coding specificity, and operational settings for 0266U. Data not available in the input is noted where applicable, and the focus remains on national-level interpretation rather than state-specific guidance.
Billing Code Overview
CPT code 0266U is a Proprietary Laboratory Analyses (PLA) code for the Praxis Transcriptome test from Praxis Genomics LLC. The assay uses transcriptome analysis and next-generation sequencing (NGS) to detect gene expression changes associated with constitutional or other heritable disorders. Report 0266U only for this specific manufacturer’s test performed on specimens such as blood, frozen tissue, or formalin–fixed paraffin–embedded (FFPE) tissue.
Service type: Laboratory molecular diagnostic testing using NGS-based transcriptome analysis
Typical site of service: Clinical laboratory or reference pathology laboratory; specimens collected in outpatient clinics, hospitals, or specialized collection centers
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with a suspected constitutional or heritable genetic disorder is referred for transcriptome testing after initial genetic evaluation. The patient presents with unexplained developmental delay, multiple congenital anomalies, neuromuscular signs, or a family history suggesting a hereditary syndrome. A geneticist, neurologist, or clinical molecular pathologist orders the 0266U Praxis Transcriptome test to evaluate gene expression signatures from a submitted specimen (peripheral blood, frozen tissue, or formalin–fixed paraffin–embedded tissue).
Specimen collection occurs in an outpatient clinic, hospital inpatient unit, or surgical pathology suite depending on the tissue source. For blood, a phlebotomist draws EDTA tube(s) and ships per laboratory instructions. For FFPE or frozen tissue, the surgical team or pathology department prepares and sends the block or fresh/frozen samples with appropriate chain-of-custody and requisition. The laboratory performs RNA extraction, next-generation sequencing (NGS) transcriptome analysis, bioinformatic processing, and clinical interpretation to determine presence or absence of gene expression changes associated with constitutional or heritable disorders. Results report is routed to the ordering clinician for correlation with clinical findings and family counseling. Billing for the proprietary laboratory analysis is reported using 0266U with applicable modifiers to indicate professional/technical components, bilateral procedures, unusual circumstances, or payer-specific reporting requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|